Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC20271 LUT014 Featured LUT014 is a novel BRAF agonist.
DC12117 Luteolin 7-O-glucuronide (Luteolin 7-glucuronide4) Featured Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively.
DC12118 Luteolin-3-O-beta-D-glucuronide Luteolin-3-O-beta-D-glucuronide is a luteolin glucosiduronic acid consisting of luteolin having a beta-D-glucosiduronic acid residue attached at the 3'-position.
DC12120 Luteolin-7-rutinoside Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.
DC11172 LV-320 LV-320 (LV320) is a novel potent, cell-active, allosteric inhibitor of the autophagy-related cysteine protease ATG4B with IC50 of 24.5 uM in ATG4B cleavage assays.
DC23133 LX-1031 LX-1031 is a potent, orally active tryptophan 5-hydroxylase (TPH) inhibitor with potency of 10-100 nM, reduces 5-HT synthesis peripherally.
DC7456 LX1606 Hippurate Featured LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.
DC10754 LX2343 Featured LX-2343 is a novel non-ATP competitive PI3K inhibitor, negatively regulating AKT/mTOR signaling, thus promoting autophagy, and increasing A-beta clearance.
DC10765 LX-2761 LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.
DC21251 LX-2931 LX-2931 (LX2931) is a potent, selective and orally bioavailable S1P lyase (S1PL) inhibitor.
DC7921 Sotagliflozin (LX-4211) Featured LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.
DC23136 LX7101 LX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively.
DC10828 LXH254 Featured LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor.
DC2072 LXR623 Featured LXR-623 is a novel Liver X Receptor modulator
DC26012 LXS-196 Featured LXS196 is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma.
DC21256 LY 2318912 LY 2318912 is a potent, competitive, small molecule inhibitor of anandamide uptake with IC50 of 7.27 nM, shows high affinity against anandamide transporter binding site with Kd o f7.62 nM.
DC8602 LY311727 Featured LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.
DC23633 LY 392098 LY 392098 is a selective, potent and centrally active positive allosteric modulator of AMPAR.
DC7944 LY2090314 Featured LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively.
DC7189 LY-2109761 LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2.
DC8435 LY2119620 Featured LY2119620 is a specific, and allosteric agonist of human M2 and M4 muscarinic acetylcholine receptors.
DC6306 LY2157299(Galunisertib) Featured LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2.
DC2045 LY2183240 LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM).
DC8630 Ralimetinib 2MsOH(LY2228820) Featured LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively).
DC12130 LY223982 LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC50 of 13.2 nM against [3H]LTB4 binding to LTB4 receptor.
DC9304 LY2334737 Featured LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.
DC9975 Ly 2365109 Hydrochloride;n-[2-[4-(1,3-benzodioxol-5-yl)-2-(1,1-dimethylethyl)phenoxy]ethyl]-n-methylglycinehydrochloride Featured LY2365109 is a potent and selective GlyT1 inhibitors with IC50 value of 15.8 nM.
DC8065 LY2409881 trihydrochloride Featured LY2409881 is a novel inhibitor of IκB kinase β (IKK2).
DC23720 LY2452473 Featured LY2452473 is an orally bioavailable, selective androgen receptor modulator (SARM).
DC10782 LY2510924 Featured LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X